Phase-I-Studie eines Prüfmedikaments gegen Pocken
Eine randomisierte, doppelblinde, explorative Crossover-Studie der Phase I zur Pharmakokinetik einer oralen Einzeldosis von Form-I-Kapseln der Anti-Orthopoxvirus-Verbindung ST-246® im Vergleich zu Form-V-Kapseln bei normal ernährten gesunden Freiwilligen
The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This was a Phase I, double-blind, cross-over, single-dose study of the orally administered anti-orthopoxvirus compound, ST-246, to 12 healthy, fed volunteers between the ages of 18 and 50 years. Subjects were randomized such that 6 subjects received either ST-246 Form I (monohydrate) followed 10 days later after a wash-out period by Form V (hemihydrate), and 6 subjects received ST-246 Form V followed by Form I, as for the previous group.
Both forms of ST-246 were similar in the way they were manufactured. The only difference between Form I and Form V may be related to how it dissolves, and this may affect the way that it is absorbed in the human body. Information about any side-effects that may occur will also be collected in this study.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Florida
-
Orlando, Florida, Vereinigte Staaten, 32809
- Orlando Clinical Research Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- 18 to 50 years
- Available for clinical follow-up duration of study.
- Able/willing to give written consent.
- Good general health; no clinically significant medical history.
- Refrain from taking any medications from screening through 72 hours after last dose.
- Adequate venous access.
- PE and lab results without clinically significant findings within 28 days prior to receipt of drug.
- Meet Lab Criteria within 28 days prior to receipt of drug.
- Negative pregnancy test
- Non smokers
- No alcohol or caffeine
- Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study
Exclusion Criteria:
-
Marked baseline prolongation of QT/corrected QT interval (QTc) interval (
-
History of additional risk factors for Torsade de Pointes
-
Clinically significant abnormal ECG
-
Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval
-
Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.
-
History of any clinically significant conditions including:
- Asthma
- Diabetes mellitus
- History of thyroidectomy or thyroid disease
- Serious angioedema episodes
- Head trauma resulting in a diagnosis of TBI other than concussion
- Seizure or history of seizure
- Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws
- Malignancy
-
Family history of idiopathic seizures
-
History or presence of neutropenia or other blood dyscrasia
-
Known Hepatitis B or Hepatitis C infection
-
Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.
-
Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.
-
Known clinically significant chronic viral infection (or current clinically significant viral infection
-
History of frequent or severe headaches or migraines
-
Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection
-
Woman who is pregnant or is breast-feeding or planning to become pregnant
-
On any concomitant medications
-
History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.
-
Inability to swallow medication
-
Body Mass Index above 35 or below 18,
-
Current drug abuse or alcohol abuse.
-
Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice
-
Clinically significant lactose intolerance
-
Received experimental drug within 30 days
-
Vaccination within 30 days
-
Total of more than 350 milliliters (mL) of blood drawn in 2 months
-
Treatment with any immunosuppressant or immunomodulatory medication in 3 months
-
Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol
-
History or diagnosis that would affect absorption of study medication
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Verdreifachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Group ST-246 Form I (followed by Form V)
Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat. |
First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
Andere Namen:
Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Andere Namen:
|
|
Aktiver Komparator: Group ST-246 Form V (followed by Form I)
Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat. |
First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
Andere Namen:
Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: t½
Zeitfenster: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Mean terminal half-life (t½; hrs) for Forms I and V were calculated from [plasma] vs time profiles. |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-τ
Zeitfenster: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Area under the drug concentration-time curve from time zero to time t, where t is the last timepoint with a drug concentration ≥ lowest obtainable quantification (AUC0-τ; ng*hr/mL). |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: AUC0-∞
Zeitfenster: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Area under the drug concentration-time curve from time zero to infinity (AUC0-∞; ng*hr/mL). |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Cmax
Zeitfenster: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Maximum drug concentration in plasma, determined directly from individual concentration-time data (Cmax) |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
|
Pharmacokinetic Parameters for a Single Dose of ST-246 Form I vs. Form V: Tmax
Zeitfenster: Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Time to maximum plasma concentration(Tmax; hrs) for Forms I and V were calculated from [plasma] vs time profiles. |
Post-dose samples at 0.5,1,2,3,4,8,12,24,36,48,72 hrs
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Study Participants Who Tolerated a Single Dose of ST-246 Form I vs. Form V as Determined by No Clinically Significant Changes in Safety Parameters
Zeitfenster: 4 weeks
|
Evaluated safety parameters included:
|
4 weeks
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Thomas C Marbury, MD, Orlando Clinical Research Center
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- SIGA-246-005
- HHSN266200600014C (Andere Zuschuss-/Finanzierungsnummer: NIAID)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .